Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Agios Pharmaceuticals (AGIO) EBIT Margin (2016 - 2025)

Historic EBIT Margin for Agios Pharmaceuticals (AGIO) over the last 13 years, with Q3 2025 value amounting to 907.37%.

  • Agios Pharmaceuticals' EBIT Margin rose 2395600.0% to 907.37% in Q3 2025 from the same period last year, while for Sep 2025 it was 1061.8%, marking a year-over-year increase of 1763000.0%. This contributed to the annual value of 1166.47% for FY2024, which is 2930500.0% up from last year.
  • As of Q3 2025, Agios Pharmaceuticals' EBIT Margin stood at 907.37%, which was up 2395600.0% from 1020.12% recorded in Q2 2025.
  • Agios Pharmaceuticals' 5-year EBIT Margin high stood at 907.37% for Q3 2025, and its period low was 12156.85% during Q1 2022.
  • Moreover, its 4-year median value for EBIT Margin was 1363.66% (2023), whereas its average is 2165.56%.
  • In the last 5 years, Agios Pharmaceuticals' EBIT Margin skyrocketed by 105413600bps in 2023 and then plummeted by -976300bps in 2025.
  • Quarter analysis of 4 years shows Agios Pharmaceuticals' EBIT Margin stood at 2300.97% in 2022, then skyrocketed by 35bps to 1496.23% in 2023, then grew by 22bps to 1165.3% in 2024, then grew by 22bps to 907.37% in 2025.
  • Its last three reported values are 907.37% in Q3 2025, 1020.12% for Q2 2025, and 1221.97% during Q1 2025.